Alembic Ltd Dividend 2026 — ₹2.40 Final, Record Date 4 Aug, Yield 2.63%

The one-line story: Alembic Limited is not an operating company you buy for its factories — it is a holding vehicle that owns a 28.41% stake in listed Alembic Pharmaceuticals plus a real-estate business. Its entire ₹61.63 crore payout is almost exactly matched by the ₹62.95 crore of dividend it receives from that pharma stake. In effect, the dividend is largely passed through, not earned from day-to-day operations.

On 19 May 2026, the Board of Directors of Alembic Limited (in a meeting held from 4:30 p.m. to 5:45 p.m.) recommended a final dividend of ₹2.40 per equity share (120% of the ₹2 face value) for the financial year ended 31 March 2026. The same board meeting approved the audited standalone and consolidated results, which carry an unmodified (clean) audit opinion from CNK & Associates LLP.

Eligibility rule: To receive this dividend you must hold shares at the end of the record date (4 Aug 2026). Because Indian settlement is now T+1, you must buy on or before the ex-date (3 Aug 2026). Buy on the ex-date or later and the seller keeps the dividend.

A 2.63% yield is above the healthcare-sector average (roughly 1.7%–1.8%, per TipRanks — not independently verified), but it is modest in absolute terms. Importantly, the yield here is not being propped up by a collapsing share price in the usual dangerous way: the stock is down about 20% over one year, yet the dividend has been held flat at ₹2.40 for three straight years. So the yield has crept up mainly because the price fell, while the payout stayed the same — a point worth understanding before treating 2.63% as "income growth."

The number aggregators miss: the headline "consolidated profit up 2.2%" hides the fact that Alembic's own profit fell 12.9%. The consolidated bottom line was rescued entirely by a +15.3% rise in the associate's (Alembic Pharma's) profit share to ₹191.5 crore — a non-cash, equity-accounted number that Alembic does not control day-to-day. On a standalone basis, net profit fell from ₹141.95 Cr to ₹124.54 Cr (−12.3%), and standalone EPS slipped from ₹5.53 to ₹4.85.

Reported profits are opinions; cash is fact. Alembic's consolidated operating cash flow rose to ₹120.07 crore (FY25: ₹86.37 Cr) — healthy, and it comfortably covers the ₹61.63 crore dividend at 1.95×. But there is a catch in free cash flow.

The key insight: after ₹76.65 crore of capital spending (largely on investment property), reported free cash flow of ₹43.42 crore is below the ₹61.63 crore dividend — a coverage of just 0.70×. That looks alarming until you see how a holding company actually works. Alembic's cash-flow statement strips the ₹62.95 crore of dividend received from Alembic Pharma out of operating cash flow and parks it under investing. Add that pass-through back and the picture flips: OCF + dividend received − capex = ₹106.4 crore, or 1.73× cover. So the dividend is funded from current cash generation (chiefly the pharma dividend it collects), not from borrowings or asset sales.

How the dividend is funded

Dividend received from Alembic Pharma: ₹62.95 Cr → Dividend paid out by Alembic: ₹61.63 Cr. That is a near-perfect 1.02× pass-through. Working capital also released cash this year (inventories fell by ₹47 Cr). Funding source: current earnings / dividend receipts — not cash reserves, not asset sales, not debt.

The hidden value story: the biggest asset on Alembic's books is its ₹1,704 crore equity-method investment in Alembic Pharma, carried at cost-plus-share-of-profits. On the market, per Screener, Alembic's investments are worth about ₹3,886 crore — more than the company's entire market capitalisation of ~₹2,340 crore. In plain terms, the stock market values the whole company at less than its listed stake in Alembic Pharma, a textbook holding-company discount. Cash-and-investment cover for the dividend is deep: even counting only readily identifiable investments, it is 4.4×.

One caveat on reserves: a large negative Other Comprehensive Income entry of about −₹105.6 Cr (fair-value marks on investments) sat below the line this year. It does not touch distributable profit or the dividend, but it is why total comprehensive income (₹229.8 Cr) came in well below net profit (₹317.4 Cr).

Overall verdict: Sustainable — with one dependency flag. Four of five tests pass comfortably. The only amber light is reported FCF (0.70×), which reflects heavy investment-property capex rather than a payout that outstrips earnings. The real sustainability question is not Alembic's own operations — it is whether Alembic Pharma keeps paying its dividend. Because roughly ₹63 of every ₹62 Alembic distributes comes from the pharma dividend it receives, the parent's payout is only as durable as its associate's. Payout is a modest 19.4% of consolidated profit, but a heavier 49.5% of standalone profit — so on its own-business earnings there is less room to spare.

Alembic Ltd is hard to peer-map because it is really a holding company, not a pure operating business. On yield (2.63%) it screens higher than both its own pharma associate (~1.2%) and the sector average, and it carries almost no debt. But its low P/E (~7.4×) and sub-market ROE (~13%) reflect the classic holding-company discount rather than obvious cheapness.

With promoters owning nearly 71%, about ₹43.68 crore of the ₹61.63 crore payout flows to the promoter group, and public shareholders receive roughly ₹16.99 crore. Promoter holding has been rock-steady at 70.88% across the last five quarters, with no pledging flagged — a sign of stable control and aligned interests, though it also means minority holders have limited sway over payout policy.

Since April 2020, dividends are taxed in the investor's hands at their income-tax slab rate (there is no longer a Dividend Distribution Tax paid by the company). The company deducts TDS at 10% under Section 194 only if your total dividend from that company in a financial year exceeds ₹10,000 (threshold raised from ₹5,000 with effect from FY2025-26). Submitting Form 15G/15H can avoid TDS if your income is below the taxable limit.

Worked example — investor holding 1,000 shares

Illustrative only; ignores surcharge/cess nuances and assumes the 30% slab. Consult a tax adviser for your own situation.

Alembic Limited's ₹2.40 final dividend (2.63% yield) is best understood for what it really is: the relay of a dividend collected from Alembic Pharmaceuticals, not a reward earned from booming operations. On the positives, the company is almost debt-free, sits on investments worth more than its entire market cap, has never cut its dividend, and covers the payout comfortably on earnings (5.15× consolidated) and operating cash flow (1.95×).

We present the evidence — positives, negatives, risks and monitoring points — and leave the decision to you. This is analysis, not advice.